List of Excipients in Branded Drug CALCIUM ACETATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Medical Care North America	CALCIUM ACETATE	calcium acetate	49230-644	GELATIN
Fresenius Medical Care North America	CALCIUM ACETATE	calcium acetate	49230-644	MINERAL OIL
Fresenius Medical Care North America	CALCIUM ACETATE	calcium acetate	49230-644	POLYETHYLENE GLYCOL 8000

Generic Drugs Containing CALCIUM ACETATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	calcium acetate	0054-0088	FD&C BLUE NO. 1
Hikma Pharmaceuticals USA Inc	calcium acetate	0054-0088	FD&C RED NO. 3
Hikma Pharmaceuticals USA Inc	calcium acetate	0054-0088	FERROSOFERRIC OXIDE
Hikma Pharmaceuticals USA Inc	calcium acetate	0054-0088	GELATIN

What are the Most Frequently-Used Excipients in CALCIUM ACETATE?

# Of NDCs	Excipient
15	ALCOHOL
3	ALUMINUM OXIDE
7	AMMONIA
4	ANHYDROUS CITRIC ACID

Calcium Acetate Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Calcium acetate is a mature, low-cost phosphate binder used to control serum phosphorus in patients with end-stage renal disease on dialysis. Its commercial value is concentrated in formulation execution rather than core-compound exclusivity. The strongest opportunities are lower pill burden, improved swallowability, powder or suspension formats, taste masking, adherence support, and cost-efficient manufacturing.

What is calcium acetate used for and how does it work?

Calcium acetate is an oral phosphate binder indicated for the reduction of serum phosphorus in patients with end-stage renal disease. It binds dietary phosphate in the gastrointestinal tract and forms insoluble calcium phosphate, which is excreted in feces rather than absorbed systemically.[1]

A common marketed strength contains 667 mg of calcium acetate, equivalent to approximately 169 mg of elemental calcium. Label dosing commonly begins at two capsules or tablets with each meal and is adjusted according to serum phosphorus levels.[1]

Product characteristic	Commercial relevance
Active ingredient	Calcium acetate
Main indication	Hyperphosphatemia in dialysis patients
Typical strength	667 mg calcium acetate
Elemental calcium per 667 mg	Approximately 169 mg
Administration	With meals
Primary dosage forms	Capsules and tablets
Main competitors	Sevelamer, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide
Core clinical constraint	Hypercalcemia and calcium loading
Primary market advantage	Low acquisition cost

The product is administered with food because phosphate binding depends on contact with dietary phosphate. This requirement creates a direct commercial link between dosage form design, patient adherence, and treatment performance.

What excipients are used in calcium acetate products?

Calcium acetate excipients vary by manufacturer, dosage form, and market. Common excipient classes include gelatin, microcrystalline cellulose, starches, colloidal silicon dioxide, magnesium stearate, talc, sodium lauryl sulfate, and capsule colorants.[2]

The inactive ingredients are generally selected for manufacturability and dose uniformity rather than pharmacologic activity. A 667 mg calcium acetate capsule has a substantial active load, which limits the amount of excipient that can be added without increasing capsule size.

Typical excipient functions

Excipient class	Function in calcium acetate formulation	Key development issue
Microcrystalline cellulose	Filler, binder, compressibility aid	Can increase tablet mass and affect disintegration
Pregelatinized starch	Binder and disintegrant	Moisture sensitivity and granulation control
Crospovidone or croscarmellose sodium	Rapid disintegration	Compatibility and tablet friability
Colloidal silicon dioxide	Glidant, flow aid	Overuse can impair compaction
Magnesium stearate	Lubricant	Excessive levels can slow wetting and dissolution
Talc	Glidant or anti-adherent	Regulatory and patient-perception considerations
Gelatin or hypromellose	Capsule shell	Shell size, moisture transfer, and dietary preferences
Film coating polymers	Protection, appearance, swallowability	Adds processing cost and tablet weight
Sweeteners and flavors	Taste masking for liquids or chewables	Calcium salt taste and mineral aftertaste
Suspending agents	Physical stability in oral liquids	Sedimentation, redispersibility, and dose uniformity

Because calcium acetate is highly dosed, excipient selection must preserve a high active-to-total-weight ratio. A formulation that improves handling but increases tablet size may reduce adherence.

How should excipients be selected for calcium acetate?

The optimal excipient strategy depends on the target product format. Conventional capsules and tablets should prioritize dose uniformity, low tablet mass, rapid disintegration, mechanical strength, and low manufacturing cost. Differentiated products should prioritize swallowability, taste masking, portability, and administration with meals.

Conventional capsule strategy

Capsules remain commercially attractive because they avoid high compression forces associated with a high-load calcium salt. A hard gelatin capsule can accommodate the dose with relatively simple blending and encapsulation.

Key formulation priorities include:

• High powder-flow performance
• Narrow particle-size distribution
• Low segregation risk
• Reliable capsule fill-weight control
• Minimal lubricant concentration
• Low moisture variability
• Adequate disintegration after storage

Microcrystalline cellulose and colloidal silicon dioxide are practical excipient combinations for improving flow and content uniformity. Excessive hydrophobic lubrication can delay wetting and disintegration, particularly where the formulation uses magnesium stearate at higher levels.

Immediate-release tablet strategy

Tablets can reduce packaging and manufacturing cost, but calcium acetate’s high dose can produce large or dense units. Direct compression may be feasible when the active ingredient has adequate flow and compactability. Roller compaction or wet granulation may be used when flow or segregation is inadequate.

The main tablet risks are:

• Excessive tablet size
• Capping or lamination
• Slow disintegration
• Poor content uniformity
• High friability after transport
• Difficult swallowing

A robust tablet platform would use a high-efficiency filler-binder, a fast disintegrant, and a low-level lubricant. Film coating may improve swallowability and reduce chalkiness, but the coating must not materially slow disintegration.

Chewable tablet strategy

A chewable calcium acetate product could address patients who have difficulty swallowing multiple capsules. Its principal challenges are taste, mouthfeel, dose size, and calcium-related grittiness.

A viable approach may combine:

• Compressible mannitol or isomalt for mouthfeel
• High-intensity sweeteners
• Flavor systems compatible with mineral salts
• Polymer-based taste masking
• Controlled particle-size calcium acetate
• A porous or rapidly disintegrating matrix

Chewable tablets could command a modest price premium if they materially improve adherence. They would also face greater formulation complexity and a higher risk of negative sensory feedback.

Powder and oral suspension strategy

A powder for constitution or ready-to-use suspension could reduce swallowing burden and support administration in patients with dysphagia. A powder product is more commercially practical than a liquid if stability and packaging costs are concerns.

The formulation must address:

• Sedimentation and caking
• Redispersibility
• Dose uniformity after shaking
• Palatability
• Water-quality effects
• Microbial control for aqueous products
• In-use stability
• Accurate dosing devices

For a ready-to-use suspension, suspending agents such as xanthan gum, hydroxypropyl cellulose, or other pharmaceutical-grade polymers may be considered. The formulation should avoid excessive viscosity, which can interfere with dose delivery and patient acceptance.

Unit-dose sachets could create a differentiated product for dialysis centers, institutional pharmacies, and patients who need portable meal-linked dosing. Sachets also reduce the risk of repeated bottle opening and may support adherence tracking.

What formulations are protected by calcium acetate patents?

Calcium acetate is an old active pharmaceutical ingredient with limited remaining composition-of-matter value. The commercial opportunity is therefore concentrated in formulation, delivery, manufacturing, and brand differentiation.

Potentially protectable features include:

• Chewable calcium acetate tablets
• Taste-masked oral powders
• Ready-to-use suspensions
• Effervescent or rapidly dispersible formulations
• High-dose tablets with improved disintegration
• Low-dust manufacturing processes
• Particle-engineered calcium acetate
• Unit-dose packaging combined with dosing instructions
• Combination products with other phosphate-control agents
• Formulations designed to reduce pill burden

A patent strategy would need to claim more than routine excipient substitution. A strong formulation patent would typically require a defined composition, particle-size range, manufacturing parameter, dissolution or dispersion profile, stability result, or clinically relevant usability benefit.

Routine use of microcrystalline cellulose, starch, magnesium stearate, common disintegrants, or conventional capsule shells is unlikely to create a durable barrier without unexpected performance data.

What is the FDA regulatory status of calcium acetate?

Calcium acetate is regulated in the United States as a prescription drug for hyperphosphatemia associated with end-stage renal disease. FDA-approved products include branded and generic capsule and tablet products. DailyMed lists current labeling and inactive ingredients for individual products.[1][2]

Regulatory pathway options

Product concept	Likely regulatory pathway	Development implication
Same strength and dosage form as a reference product	ANDA	Requires pharmaceutical equivalence and bioequivalence or applicable waiver
New oral suspension	Potential 505(b)(2) or ANDA, depending on reference and product design	May require additional quality and clinical bridging work
Chewable tablet	Potential 505(b)(2) or ANDA	Product-specific equivalence strategy is important
New combination product	505(b)(2) or full NDA depending on claims	Requires clinical and regulatory justification
Dietary supplement positioning	Generally unsuitable for prescription phosphate-binding claims	Disease-treatment claims trigger drug regulation

For a generic capsule or tablet, excipients must be pharmaceutically acceptable and the finished product must meet applicable quality, strength, purity, and performance requirements. A differentiated dosage form may require a 505(b)(2) application if it relies on published literature or an approved product while introducing a new formulation, route-related characteristic, or clinical use.

What is the Orange Book status of calcium acetate?

The relevant Orange Book analysis is product-specific. Calcium acetate products may be listed by reference listed drug, approved dosage form, and patent or exclusivity information. Because calcium acetate has been marketed for decades, the principal capsule and tablet categories generally present a mature generic market rather than a meaningful active patent-exclusivity barrier.[3]

For diligence, the key questions are:

1. Whether the target reference product has current listed patents.
2. Whether any listed patent covers a formulation rather than the old active ingredient.
3. Whether the proposed generic uses the same dosage form and strength.
4. Whether a Paragraph IV certification is required.
5. Whether a 30-month stay or patent litigation affects launch timing.

A new oral suspension, chewable product, or formulation with novel excipient architecture may avoid direct reliance on an existing formulation patent, but it can also face a more complex regulatory pathway.

When does calcium acetate lose exclusivity?

Calcium acetate’s basic active-ingredient exclusivity has long expired. The commercial market is driven by generic competition, purchasing contracts, supply reliability, and dosage-form differentiation rather than expected loss of core patent protection.

There is no standard remaining exclusivity period comparable to a recently approved small molecule. Any current barrier would more likely arise from:

• A product-specific formulation patent
• Pediatric exclusivity, if granted for a particular product
• Regulatory exclusivity attached to a newer dosage form
• Litigation involving a listed patent
• Manufacturing or supply constraints

The absence of core-molecule exclusivity does not eliminate commercial opportunity. It shifts value toward cost leadership and clinically useful formulation improvements.

Which companies are challenging calcium acetate products?

Calcium acetate is already subject to broad generic competition. The competitive field includes manufacturers of generic capsules and tablets, branded phosphate-binder companies, and developers of alternative non-calcium binders.

The main therapeutic competitors are:

Product	Active ingredient	Company or major commercial sponsor	Differentiation
PhosLo and equivalents	Calcium acetate	Historical branded and generic suppliers	Low-cost calcium-based binding
Renvela and generic equivalents	Sevelamer carbonate	Sanofi and generic manufacturers	Non-calcium phosphate binding
Fosrenol	Lanthanum carbonate	Takeda and generic manufacturers	High binding capacity, chewable format
Auryxia	Ferric citrate	Keryx Pharmaceuticals, now part of Akebia-related commercial operations	Phosphate binding and iron delivery
Velphoro	Sucroferric oxyhydroxide	Vifor Pharma, now within CSL-related operations	Lower pill burden and chewable administration

Calcium acetate competes effectively on price but is disadvantaged where clinicians seek to limit calcium exposure. A new calcium acetate product therefore needs either a lower total treatment burden or a meaningful adherence advantage.

How strong is the calcium acetate patent estate?

The core patent estate is weak as a barrier to generic entry because the active ingredient and conventional dosage forms are mature. A new entrant should not assume that a capsule or immediate-release tablet with routine excipients will support meaningful patent exclusivity.

Patent strength is higher in narrow, data-supported areas:

• Novel particle engineering
• Improved taste masking
• Stable liquid systems
• Low-volume high-concentration suspensions
• Rapidly dispersible powders
• Meal-linked unit-dose systems
• Manufacturing methods that improve uniformity or reduce defects

A commercially credible patent portfolio would normally combine composition claims with process, dosage-form, and use claims. The claims should be supported by comparative data against standard calcium acetate capsules or tablets.

What generic entry risks exist for calcium acetate?

Generic entry risk is high for conventional capsules and tablets. A sponsor pursuing a standard product should expect price competition, limited differentiation, and possible contract-manufacturing pressure.

Risk is lower, but development complexity is higher, for:

• Taste-masked liquids
• Pediatric or dysphagia-oriented dosage forms
• Chewable tablets
• Unit-dose powders
• Products with lower pill burden
• Products supported by adherence or patient-preference data

Potential launch scenarios include:

Launch scenario	Market outcome
Commodity 667 mg capsule	Rapid price erosion and pharmacy substitution
Lower-cost tablet	Moderate share opportunity through tenders and wholesalers
Chewable tablet	Premium niche if sensory profile is acceptable
Oral suspension	Differentiated institutional and dysphagia opportunity
Unit-dose powder	Specialty pharmacy, dialysis-center, and adherence opportunity
Combination phosphate-binder product	Higher regulatory and clinical burden, potentially stronger differentiation

What commercial opportunities exist for calcium acetate?

The most actionable opportunities are formulation-led.

1. Lower pill burden

Patients may take several units with each meal. A higher-load tablet or granulated sachet could reduce daily unit count, provided the product remains swallowable and dose-flexible.

2. Dysphagia and geriatric formulations

Dialysis populations include older adults and patients with swallowing difficulties. A dispersible powder, oral suspension, or small-volume liquid could address an underserved administration problem.

3. Dialysis-center supply

Unit-dose packaging, barcoded meal-linked dosing, and tamper-evident sachets could support institutional distribution. Packaging convenience may be more valuable than a modest change in excipient composition.

4. Cost-efficient generic supply

Reliable API sourcing, high-throughput encapsulation, and low-defect tablet compression can create value in a market where buyers prioritize uninterrupted supply and low acquisition cost.

5. International markets

Geographic opportunities are strongest where calcium-based phosphate binders remain widely used because of reimbursement constraints. Regulatory requirements, elemental-calcium labeling, local pharmacopoeias, and dialysis procurement practices must be assessed country by country.

How does calcium acetate compare with non-calcium phosphate binders?

Calcium acetate has a price advantage but creates calcium-loading concerns. Sevelamer, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide offer non-calcium or lower-calcium alternatives, but their acquisition costs and dosage-form profiles differ.

Attribute	Calcium acetate	Sevelamer	Lanthanum carbonate	Ferric citrate	Sucroferric oxyhydroxide
Calcium exposure	Yes	No	No	No	No
Cost positioning	Low	Higher	Higher	Higher	Higher
Typical adherence issue	Multiple units and meal timing	High pill burden	Chewability	GI effects and iron-related considerations	Chewable administration
Excipient opportunity	High in low-cost differentiated formats	Moderate	Sensory and chewable design	Taste and tablet design	Chewability and texture
Patent barrier for mature products	Limited for calcium acetate	Product-specific	Product-specific	Product-specific	Product-specific

Calcium acetate is most defensible as a cost-effective product with better administration characteristics, not as a premium molecule.

What patent litigation and settlement issues affect calcium acetate?

The major litigation risk for a new calcium acetate capsule or tablet is likely to be limited because the active ingredient is mature and generic competition is established. Any meaningful risk would depend on current Orange Book listings for the specific reference product and on the claims of the proposed product.

Paragraph IV activity is more relevant to newer phosphate binders than to conventional calcium acetate products. A company developing a novel dosage form should evaluate whether its product is an ANDA, 505(b)(2), or new NDA candidate before assessing litigation exposure. Settlement agreements, if any, must be reviewed in the FDA’s approved-product and patent-litigation records rather than inferred from the existence of generic competition.[3][4]

Key Takeaways

• Calcium acetate is a mature prescription phosphate binder with little core-molecule exclusivity remaining.
• Conventional capsules and tablets face high generic-entry and price-erosion risk.
• Excipient value is concentrated in flow, dose uniformity, disintegration, swallowability, taste masking, and suspension stability.
• The strongest commercial concepts are chewable tablets, oral powders, suspensions, and unit-dose meal-linked products.
• Routine excipient substitution is unlikely to support strong patent protection without comparative performance data.
• A differentiated product may require a 505(b)(2) strategy rather than a conventional ANDA.
• Calcium loading remains the principal clinical limitation against sevelamer, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide.
• Manufacturing reliability and low cost remain material competitive advantages in the generic calcium acetate market.

FAQs

Can calcium acetate be formulated as an oral liquid?

Yes. An oral liquid or suspension is technically feasible, but development must control sedimentation, redispersibility, dose uniformity, microbial quality, palatability, and in-use stability.

Is calcium acetate suitable for a 505(b)(2) application?

A new dosage form, suspension, chewable tablet, or other differentiated formulation may be suitable for a 505(b)(2) pathway, depending on the extent of reliance on an approved product and the proposed labeling.

Which excipient is best for calcium acetate tablets?

No single excipient is universally optimal. The formulation normally requires a balance among a compressible filler-binder, an effective disintegrant, a glidant, and a low-level lubricant.

Can calcium acetate be protected with a formulation patent?

Yes, but patent strength depends on novelty and evidence. A claim covering routine excipients in conventional amounts is generally weaker than a claim tied to particle engineering, stability, taste masking, or a measurable performance improvement.

Does calcium acetate have a pediatric commercial opportunity?

Potentially. A powder, suspension, or chewable formulation could address pediatric swallowing and dose-flexibility needs, but pediatric labeling and regulatory requirements would materially affect development cost.

References

1. DailyMed. (n.d.). Calcium acetate: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
2. DailyMed. (n.d.). PhosLo and calcium acetate product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/